Michael Makris/LinkedIn
Jan 19, 2026, 14:17
Michael Makris on The Benefits of Low-Dose Emicizumab in Hemophilia A
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”Another study showing the benefit of low-dose emicizumab (Hemlibra) in hemophilia A.
The patients were receiving half the approved dose of the drug.
Despite this, the mean Annual Bleed Rate (ABR) was 0.4, the median was 0.0 and 67% had zero bleeds.
If you saw these data, you would not know that the patients were only using half the approved dose.
Is it not time for a randomised study in Europe or North America of full vs half-dose emicizumab in severe hemophilia A?
Roche will clearly never do such a study, it will need to be done independently.”
Stay updated with Hemostasis Today.
-
Jun 29, 2026, 15:50Sweta Agrawal: Expanding Care for PNH Patients in Nepal
-
Jun 29, 2026, 15:17Heghine Khachatryan: Hemostasis at the Crossroads of Thrombosis and Bleeding
-
Jun 29, 2026, 15:07Tomaz Crochemore: From Bleeding to Thrombosis – The Era of Precision Hemostatic Medicine Has Arrived
-
Jun 29, 2026, 14:51Pete Stibbs: Building a Successful Venous Thrombectomy Practice
-
Jun 29, 2026, 14:30Bruno Pougault: Pregnancy and Thrombosis – Balancing Evolutionary Protection Against Clinical Risk
-
Jun 29, 2026, 13:32Omid Seidizadeh: The Full VWD Session from EHA 2026 Is Now Available to Watch
-
Jun 29, 2026, 13:22Cheryl Carcel: Make The Stroke Research More Inclusive for Women, Take The Survey
-
Jun 29, 2026, 13:18Bianca Rocca: New Expert Opinion On the Evolving Debate on Factor XI as a Therapeutic Target
-
Jun 29, 2026, 13:06Francisco Chacón-Lozsán: Intermittent Hemodialysis in the ICU Should not be Monitored Only by ‘Session Completed’